Want to see MBRX full AI Analyst Report?
MBRX Stock Chart & Stats
$2.42
-$0.01(-0.56%)
At close: 4:00 PM EST
$2.42
-$0.01(-0.56%)
Day’s Range― - ―
52-Week Range$1.79 - $24.00
Previous CloseN/A
Volume63.82K
Average Volume (3M)2.74M
Market Cap
$13.02M
Enterprise Value$4.95M
Total Cash (Recent Filing)$10.32M
Total Debt (Recent Filing)$326.00K
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Aug 19, 2026EPS Estimate
-1.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-27.98
Shares Outstanding5,336,350
10 Day Avg. Volume1,958,319
30 Day Avg. Volume2,738,732
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.26
Price to Sales (P/S)0.00
P/FCF Ratio-0.17
Enterprise Value/Market Cap0.38
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-133.80
Enterprise Value/Ebitda-0.16
Forecast
1Y Price Target
$16.00Price Target Upside561.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-4.6
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pivotal Trial Efficacy SignalRobust interim efficacy signals in the pivotal MIRACLE Part A (notable higher complete and composite remission rates versus control) indicate Annamycin may address a clear unmet need in relapsed/refractory AML. If sustained in larger cohorts, this underpins regulatory pathway, commercialization prospects, and durable market positioning versus standard cytarabine regimens.
Favorable Cardiac Safety ProfileDemonstrated lack of cardiotoxicity across pooled trials is a structural competitive advantage for Annamycin versus traditional anthracyclines, enabling use in heavily pretreated patients and those with prior anthracycline exposure. This safety differentiation supports broader clinical adoption, better tolerability, and stronger reimbursement/selection arguments over time.
Strengthened Patent ProtectionAdditional patents extending protection into 2040 enhance global exclusivity and commercialization optionality, particularly in Asian markets. Durable IP coverage supports licensing or partnership negotiations, preserves potential future revenue streams, and reduces the risk of generic substitution during the product life cycle if clinical development leads to approval.
Bears Say
No Revenue And Large LossesAs a pre-commercial clinical-stage biotech, Moleculin reports no product revenue and sustained net losses, reflecting R&D-focused spending without offsetting sales. This structural lack of operating revenue prolongs dependency on external financing and makes long-term viability contingent on trial success or partnering, increasing execution risk over months.
Sustained Negative Cash FlowConsistent negative operating and free cash flow at material levels implies ongoing depletion of cash reserves and recurring funding needs. Over a multi-month horizon, this raises runway and dilution risk, constrains strategic flexibility, and could force accelerated fundraising or partnership terms that are less favorable if clinical milestones are delayed.
Equity Dilution / Financing RelianceRecent warrant exercises and prior shareholder approval to issue additional shares illustrate repeated reliance on equity financing. Structural dependence on dilutive capital can erode shareholder value, limit long-term upside for existing holders, and signal that continued development and commercialization will require further equity or partner-funded financing rounds.
Moleculin Biotech News
MBRX FAQ
What was Moleculin Biotech’s price range in the past 12 months?
Moleculin Biotech lowest stock price was $1.79 and its highest was $24.00 in the past 12 months.
What is Moleculin Biotech’s market cap?
Moleculin Biotech’s market cap is $13.02M.
When is Moleculin Biotech’s upcoming earnings report date?
Moleculin Biotech’s upcoming earnings report date is Aug 19, 2026 which is in 39 days.
How were Moleculin Biotech’s earnings last quarter?
Moleculin Biotech released its earnings results on May 15, 2026. The company reported -$3.54 earnings per share for the quarter, missing the consensus estimate of -$2.333 by -$1.207.
Is Moleculin Biotech overvalued?
According to Wall Street analysts Moleculin Biotech’s price is currently Undervalued.
Does Moleculin Biotech pay dividends?
Moleculin Biotech does not currently pay dividends.
What is Moleculin Biotech’s EPS estimate?
Moleculin Biotech’s EPS estimate is -1.61.
How many shares outstanding does Moleculin Biotech have?
Moleculin Biotech has 5,336,350 shares outstanding.
What happened to Moleculin Biotech’s price movement after its last earnings report?
Moleculin Biotech reported an EPS of -$3.54 in its last earnings report, missing expectations of -$2.333. Following the earnings report the stock price went down -4.091%.
Which hedge fund is a major shareholder of Moleculin Biotech?
Currently, no hedge funds are holding shares in MBRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Moleculin Biotech
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs. WP1066, a prominent immune/transcription modulator for the company, is presently in Phase I studies, targeting both adult and pediatric brain tumors, pancreatic cancer, and other types of aggressive malignancies. Further, the firm is developing WP1220, an analog of WP1066, intended for topical application in treating cutaneous T-cell lymphoma. Another compound, WP1122, is under development for glioblastoma multiforme and COVID-19. Moleculin Biotech has established collaboration agreements and partnerships with organizations such as MD Anderson, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o. The company was founded in 2015 and maintains its principal offices in Houston, Texas.
MBRX Stock 12 Month Forecast
Average Price Target
$16.00
▲(561.16% Upside)
Technical Analysis
Ownership Overview
1.10% Insiders
0.56% Mutual Funds
1.41% Other Institutional Investors
96.40% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---